Skip to main content
PharmaGraphX
PharmaGraphX
Log inGet Started

Important Disclaimer

PharmaGraphX is a research and educational tool only. It is NOT intended for clinical decision-making, patient care, or medical advice. All drug information, calculations, interactions, and recommendations are for educational and research purposes only. Always consult qualified healthcare professionals, official drug labeling (FDA, TGA, EMA), and institutional guidelines before making any clinical decisions. The developers assume no liability for any decisions made based on information provided by this platform.

© 2026 PharmaGraphX. All rights reserved.

|

For research and educational purposes only. Not medical advice.

Help
  • Navigate between workspaces using the left sidebar.
  • Use the main chat to ask any pharmacology question.
  • Press G then H to quickly navigate home.
Navigation
HomeG H
PK/PD StudioG P
Interaction HubG A
Digital TwinG T
Molecular LabG M

Press Esc to close

  1. Home
  2. /Database
  3. /Omeprazole

Omeprazole

Prilosec, Yosprala, Talicia, Konvomep, Primeguard, Zegerid Reformulated Aug 2006, UlcerGard

Proton pump inhibitor • PPI

Premium
Nephrotoxic

Half-life

0.5-1 hour

Protein Binding

Metabolized By

CYP2C19, CYP3A4

External

Drugs.com

Mechanism of Action

Irreversibly inhibits H+/K+-ATPase in gastric parietal cells

Indications(5)

Breast CancerHealthyHealthy VolunteersEarly Gastric CancerGastric Dysplasia

Classification

Drug Class

Proton pump inhibitor

Subclass

PPI

Brand Names

PrilosecYospralaTaliciaKonvomepPrimeguardZegerid Reformulated Aug 2006UlcerGard

Key Properties

Half-life

0.5-1 hour

Time for plasma concentration to decrease by 50%

Protein Binding

—

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses

Not a substitute for clinical judgement
Omeprazole Drug Profile | PharmaGraphX